Sanofi Plans Approval Filings for Cancer, Immunology Candidates
Sanofi said today it plans nine regulatory submissions over the next 18 months, and at least 10 pivotal trials for pipeline candidates over the next 12 months—parts of an R&D strategy update of its “2020 Roadmap” offered to analysts. “2018 will be an important year as we expect multiple milestones for Sanofi's late-stage pipeline, made possible through the prioritization principles we have consistently applied to our early-stage research programs,” Elias Zerhouni, M.D., Sanofi’s global head of R&D, said in a statement. One of the nine submissions, announced separately today by the pharma giant and development partner Regeneron, will be for cemiplimab, a programmed cell death protein 1 (PD-1) checkpoint inhibitor developed for advanced cutaneous squamous cell carcinoma (CSCC). The companies released positive topline results from the study showing an overall response rate (ORR) of 46.3% for cemiplimab, which Sanofi declared was “the backbone of our checkpoint ...
Original Article: Sanofi Plans Approval Filings for Cancer, Immunology Candidates
